Home > Analyse
Actualite financiere : Actualite bourse

GSK: positive CHMP opinion to extend Arexvy approval

(CercleFinance.com) - GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended extending approval of its respiratory syncytial virus (RSV) vaccine to include adults aged 50 to 59, in addition to those aged 60 and over.


This is the first time that such a recommendation has been made for this age group by the CHMP.

The European Commission's final decision is expected in September 2024. Since June 2023, Arexvy vaccine has already been approved in Europe for adults aged 60 and over.


Copyright (c) 2024 CercleFinance.com. All rights reserved.